BMEA Stock Forecast: Biomea Fusion, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.58
−1.65% on the day

The median 12-month analyst price target for Biomea Fusion, Inc. is $6. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 46 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$41.7M
Ticker Nerd rank
46/ 100
Median analyst target
$6.00
Analysts covering
7
Revenue$0.0
Operating income−$12.8M
Net income−$8.3M
Free cash flow−$10.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
−21.4%
YTD
−53.4%
1Y
−42.2%
From 52W high
−73.8%
From 52W low
+18.5%
$0.49
$2.21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
46/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
75
Revisions
68
Issuance
67
Accruals
42
Volatility
31
Quality
30
Value
28
Momentum
14

Growth (75): Sales and profits are climbing, and climbing faster than before.

Momentum (14): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

BMEA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26BMEAHigh $10.00Median $6.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6
Buy
0
Hold
1
Sell
$4.00
Low
$6.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Oct 2026CitizensReiteratesMarket Outperform$7.00
14 Oct 2026HC Wainwright & Co.ReiteratesBuy$4.00
7 Oct 2026Brookline CapitalInitiatesBuy$10
5 May 2026CitizensInitiatesMarket Outperform$9.00
28 Apr 2026D. Boral CapitalMaintainsBuy$12
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
13 Jan 2026D. Boral CapitalMaintainsBuy—
10 Nov 2025CitigroupMaintainsBuy—
5 Nov 2025D. Boral CapitalMaintainsBuy—
27 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
3 Oct 2025D. Boral CapitalMaintainsBuy—
28 Aug 2025JefferiesInitiatesBuy—
11 Aug 2025CitigroupMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025ScotiabankMaintainsSector Outperform—
21 July 2025D. Boral CapitalMaintainsBuy—
16 July 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BMEA.

Market Radar

This page is one stock. Monday covers all of them.

BMEA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

BMEA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Biomea Fusion, Inc. returned −42.2% against +6.9% for the S&P 500, dividends included.

BMEA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26BMEAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMEA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
5.5×

Cheaper than 16% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−192.3%

Higher than 8% of US stocks

Return on assets
−75.4%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biomea Fusion, Inc. has a market value of $41.7M and an enterprise value of $15.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$32.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 72.5M.

  • Biomea Fusion, Inc. employs 34 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

BMEA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BMEABiomea Fusion, Inc.$41.7M46
OSTXOS Therapies, Inc.$42.0M23
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
ELTXElicio Therapeutics, Inc.$41.0M51
ELOXEloxx Pharmaceuticals, Inc.$43.1M18
SPROSpero Therapeutics, Inc.$43.2M32
INKTMiNK Therapeutics, Inc.$39.8M62

Take a look at BMEA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about BMEA

What is the BMEA stock price forecast for 2026-2027?

The median 12-month analyst price target for Biomea Fusion, Inc. is $6, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMEA stock a buy right now?

Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 46 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMEA?

As at 21 Nov 2026, Biomea Fusion, Inc. ranks 46 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (75 of 100).

Will BMEA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $6, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 46 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMEA stock forecast for 2030?

No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has BMEA stock performed over the past year?

Biomea Fusion, Inc. returned -42.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biomea Fusion, Inc. do?

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity.

Company

About Biomea Fusion, Inc.

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.

CEO Dr. Michael J. M. Hitchcock Ph.D. · 34 employees · United States · https://biomeafusion.com